PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › Trastuzumab

Drugs in development · updated 30 October 2026

Trastuzumab: clinical trials and development status

Other names and codes: Herceptin, Herzuma, Hercessi, Ontruzant, Trazimera, Ogivri

NLM verified identityApproved in the US (FDA)Authorised in the EU (EMA) since 28 August 2000

As of 30 October 2026 Trastuzumab is in 220 active clinical trials (recruiting or ongoing, phases I–III) for 54 diseases. The most advanced phase is III.

220Active trials
IIIMost advanced phase
54Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow Trastuzumab and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov. Showing 30 of 54 diseases.

DiseaseMost advanced phaseActive trialsReference trial
Breast neoplasmIII108NCT02947685
Stomach neoplasmIII18NCT05152147
Colorectal neoplasmIII13NCT05253651
NeoplasmIII10NCT05256225
Esophageal neoplasmIII8NCT05152147
MetastasisIII8NCT04784715
Biliary tract neoplasmIII5NCT05615818
Endometrial neoplasmIII5NCT05256225
Esophagus adenocarcinomaIII5NCT05152147
Lung neoplasmII–III5NCT05786716
Ovarian neoplasmIII5NCT07779538
Hematologic neoplasmII–III4NCT05722886
Colonic neoplasmIII3NCT03803553
Gallbladder neoplasmII–III3NCT05786716
Pancreatic neoplasmII–III3NCT05786716
Salivary gland neoplasmII–III3NCT05786716
Bladder neoplasmII–III2NCT05786716
Breast diseaseIII2NCT04784715
Prostatic NeoplasmsII–III2NCT05786716
Lymphoproliferative disordersII–III1NCT05722886
Skin neoplasmII–III1NCT05786716
Non-small-cell lung carcinomaII5NCT04579380
Meningeal neoplasmII4NCT07694986
Triple-negative breast neoplasmII4NCT06649331
AdenocarcinomaII3NCT04379596
Multiple myelomaII3NCT02465060
Uterine cervix neoplasmII3NCT02465060
Brain NeoplasmsII2NCT05323955
CholangiocarcinomaII2NCT06178445
Head and neck squamous cell carcinomaI–II2NCT05785741

Everything on Trastuzumab

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch